| Literature DB >> 25331880 |
Xinjiang Kang1, Huadong Xu1, Sasa Teng1, Xiaoyu Zhang1, Zijun Deng1, Li Zhou1, Panli Zuo1, Bing Liu1, Bin Liu1, Qihui Wu1, Li Wang1, Meiqin Hu1, Haiqiang Dou1, Wei Liu1, Feipeng Zhu1, Qing Li1, Shu Guo1, Jingli Gu1, Qian Lei1, Jing Lü1, Yu Mu1, Mu Jin1, Shirong Wang1, Wei Jiang2, Kun Liu3, Changhe Wang1, Wenlin Li4, Kang Zhang5, Zhuan Zhou6.
Abstract
Embryonic stem cell-based therapies exhibit great potential for the treatment of Parkinson's disease (PD) because they can significantly rescue PD-like behaviors. However, whether the transplanted cells themselves release dopamine in vivo remains elusive. We and others have recently induced human embryonic stem cells into primitive neural stem cells (pNSCs) that are self-renewable for massive/transplantable production and can efficiently differentiate into dopamine-like neurons (pNSC-DAn) in culture. Here, we showed that after the striatal transplantation of pNSC-DAn, (i) pNSC-DAn retained tyrosine hydroxylase expression and reduced PD-like asymmetric rotation; (ii) depolarization-evoked dopamine release and reuptake were significantly rescued in the striatum both in vitro (brain slices) and in vivo, as determined jointly by microdialysis-based HPLC and electrochemical carbon fiber electrodes; and (iii) the rescued dopamine was released directly from the grafted pNSC-DAn (and not from injured original cells). Thus, pNSC-DAn grafts release and reuptake dopamine in the striatum in vivo and alleviate PD symptoms in rats, providing proof-of-concept for human clinical translation.Entities:
Keywords: CFE; Parkinson's disease; dopamine; neural stem cells; striatum in vivo
Mesh:
Substances:
Year: 2014 PMID: 25331880 PMCID: PMC4226131 DOI: 10.1073/pnas.1408484111
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205